Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Deal Watch: Galenica Offers For Relypsa, But Other Suitors May Emerge

Jul 21 2016

• By Joseph Haas

Related Content

AstraZeneca's ZS-9 Timeline Hit By FDA Complete Response Letter

May 27 2016

Relypsa’s Potassium-Lowering Drug Clears FDA, But Dosing Warning Could Impact Use

Oct 22 2015

Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway

Jul 13 2016

Deal Watch: GSK Accelerates TCR Collaboration With Adaptimmune

Feb 08 2016

Jounce Gets $261m To Start, Milestone Fees Up To $2.3bn In Celgene Deal

Jul 19 2016

Chronos' Deal With Shire Is 'Just The Start' Of Its Acquisitive New Strategy

Jul 20 2016

Galderma Steps Into Biologics With Chugai Eczema Antibody

Jul 21 2016

Keeping Track: FDA Approval Activity Heats Up With Ocaliva, Zinbryta And More

Jun 06 2016

Juno Picks Up A2a Receptor Via Redox Acquisition

Jul 18 2016

Related Companies

Relypsa, Inc.

CSL Vifor

CSL Vifor

AstraZeneca PLC

ZS Pharma

Sanofi

DMK Pharmaceuticals Corp.

Allergan plc

Teva Pharmaceutical Industries Ltd.

Viatris Inc.

AbCellera Biologics Inc.

Merck & Co., Inc.

Teva Pharmaceutical Industries Ltd.

University of Massachusetts Chan Medical School

Amgen, Inc.

Daiichi Sankyo Co., Ltd.

AbbVie Inc.

Roche Holding AG

Boehringer Ingelheim GmbH

University of Dundee

Jounce Therapeutics, Inc.

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Takeda Pharmaceutical Co. Ltd.

Galderma S.A.

Chugai Pharmaceutical Co., Ltd.

Additional Topics

Commercial Deals BioPharmaceutical

More from Business

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window